| HOME >> BIOLOGY >> TECHNOLOGY |
(22) (i)
Selling,
general and
administr-
ative 900 (10) (a) 890 730 (18) (a) 804
92 (e)
Write-off of
acquired
in-process
R&D - - 590 (590) (j) -
Amortization of
intangible
assets 74 (74) (d) - 76 (73) (d) -
(3) (k)
Other
charges 12 (8) (e) - 254 (254) (e) -
(4) (f)
------- ------- ------- ------- ------- -------
Total
operating
expenses 2,392 (212) 2,180 3,218 (1,130) 2,088
------- ------- ------- ------- ------- -------
Operating
income 1,483 212 1,695 393 1,130 1,523
Interest and
other income
and (expense),
net (12) 9 (g) (3) (21) - (21)
------- ------- ------- ------- ------- -------
Income before
income taxes 1,471 221 1,692 372 1,130 1,502
Provision for
income taxes 313 71 (o) 384 171 150 (q) 321
------- ------- ------- ------- ------- -------
Net income $1,158 $150 $1,308 $201 $980 $1,181
======= ======= ======= ======= ======= =======
Earnings per
share:
Basic $1.09 $1.24 $0.19 $1.09
Diluted (r) $1.09 $1.23 (a) $0.18 $1.08 (a)
Average shares
used in
cal
'/>"/>
| SOURCE Amgen Copyright©2008 PR Newswire. All rights reserved |